Claims for Patent: 8,962,574

Summary for Patent: 8,962,574

Title:	Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
Abstract:	A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has at least one risk factor for major bleeding events, the method comprising administering to the patient 110 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.
Inventor(s):	Reilly; Paul Anthony (Danbury, CT)
Assignee:	Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:	13/128,459
Patent Claims:	1. A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has at least one risk factor for major bleeding events, the method comprising administering to the patient 110 mg b.i.d. (twice daily) of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof, and wherein the risk factor for major bleeding events includes reduced creatinine clearance of 30 mL/min or less. 2. The method according to claim 1, wherein the patient has at least two risk factors for major bleeding events. 3. The method according to claim 2, wherein a further risk factor for major bleeding events includes an age of 75 years or greater. 4. The method according to claim 2, wherein a further risk factor for major bleeding events includes a history of earlier bleeding events. 5. A method for preventing stroke in a patient with atrial fibrillation and has a reduced creatinine clearance of 30 mL/min or less, the method comprising administering 110 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof, to the patient and modifying the administration as necessary to maintain plasma levels of dabigatran in the patient between about 20 ng/mL to about 180 ng/mL, wherein the patient is at a reduced risk for a major bleeding event when compared to conventional warfarin therapy. 6. The method according to claim 5, wherein the plasma levels of dabigatran are between about 43 ng/mL to about 143 ng/mL. 7. The method according to claim 5, wherein the plasma levels of dabigatran are between about 50 ng/mL to about 120 ng/mL. 8. The method according to claim 5, wherein the plasma levels of dabigatran are between about 50 ng/mL to about 70 ng/mL. 9. The method according to claim 5, wherein the plasma levels of dabigatran are between about 60 ng/mL to about 100 ng/mL. 10. The method according to claim 5, wherein the major bleeding event is a life-threatening bleeding event. 11. The method according to claim 5, wherein the plasma levels of dabigatran is determined using the standardized lyophilized dabigatran method. 12. The method according to claim 1 or 5, wherein the dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof, is co-administered with an antiplatelet agent. 13. The method according to claim 12, wherein the antiplatelet agent is aspirin and is administered at less than or equal to 100 mg per day. 14. The method according to claim 12, wherein the antiplatelet agent is aspirin, dipyridamole, clopidogrel, abciximab, eptifibatide, tirofiban, epoprostenol, streptokinase, or a plasminogen activator. 15. The method according to claim 1 or 5, wherein the dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof, is co-administered with an antiarrhythmic agent. 16. The method according to claim 15, wherein the antiarrhythmic agent is a potassium channel blocker, sodium channel blocker, beta blocker, or calcium channel blocker. 17. The method according to claim 15, wherein the antiarrhythmic agent is quinidine, procainamide, disopyramide, lidocaine, mexiletine, tocainide, phenytoin, flecainide, encainide, propafenone, moracizine, propranolol, esmolol, metoprolol, timolol, atenolol, miodarone, sotalol, dofetilide, ibutilide, erapamil, diltiazem, amiodarone, bretylium, verapamil, diltiazem, adenosine, or digoxin. 18. The method according to claim 17, wherein the antiarrhythmic agent is quinidine.

Details for Patent 8,962,574

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2028-11-11